24 Weeks of valganciclovir prophylaxis in children after renal transplantation: A 4-year experience

Transplantation

Volumn 91, Issue 2, 2011, Pages 245-250

  Camacho Gonzalez, Andres F ^a   Gutman, Julie ^a   Hymes, Leonard C ^a   Leong, Traci ^b   Hilinski, Joseph A ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Children; CMV; Valganciclovir

Indexed keywords

THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CHILD; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PEDIATRIC SURGERY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; TREATMENT DURATION; VIREMIA;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GANCICLOVIR; HUMANS; INFANT; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 78751645814     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ffffd3     Document Type: Article

References (31)

1. Hodson EM, Craig JC, Strippoli GF, et al. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008: CD003774.
2. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganci-clovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
3. Singh N. Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 2006; 16: 281.
4. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006; 16: 289.
5. Mwintshi K, Brennan DC. Prevention and management of cytomega-lovirus infection in solid-organ transplantation. Expert Rev Anti Infect Ther 2007; 5: 295.
6. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cyto-megalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46: 840.
7. Cervera C, Pineda M, Linares L, et al. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Transplant Proc 2007; 39: 2228.
8. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalo-virus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81: 1645.
9. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease comparedtoa12-week course.Transplantation 2006; 81: 1106.
10. Zhao W, Baudouin V, Zhang D, et al. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin Pharmacokinet 2009; 48: 321.
11. Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007; 11: 301.
12. Vaudry W, Ettenger R, Jara P, et al. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009; 9: 636.
13. Cytomegalovirus. Am J Transplant 2004; 4(suppl 10): 51.
14. Robinson LG, HilinskiJ, Graham F, etal. Predictorsofcytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation. Pediatr Transplant 2002; 6: 111.
15. Renoult E, Clermont MJ, Phan V, et al. Prevention of CMV disease in pediatric kidney transplant recipients: Evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperim-mune globulin prophylaxis in high-risk patients. Pediatr Transplant 2008; 12: 420.
16. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the managementof cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134.
17. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4: 1635.
18. Humar A, Lebranchu Y, Vincenti F, et al. Long term results of the IMPACT study: 200 vs 100 daysofvalganciclovir prophylaxisin kidney recipients [abstract 350]. In: American Transplant Congress, May 1-5, 2010, San Diego, CA.
19. Parreira L, Bruges M, Gaspar A, et al. Prevention of cytomegalovirus disease in renal transplantation: Single-center experience. Transplant Proc 2009; 41: 877.
20. Brum S, Nolasco F, Sousa J, et al. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil. Transplant Proc 2008; 40: 752.
21. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study ofsolid-organ transplant recipients. J Infect Dis2004; 189: 1615.
22. Annemans L, Moeremans K, Mutimer D, et al. Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making. Value Health 2002; 5: 347.
23. GabardiS, Magee CC, Baroletti SA, et al. Efficacy and safety oflow-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis. Pharmacother-apy 2004; 24: 1323.
24. Park JM, Lake KD, Arenas JD, et al. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12: 112.
25. Weng FL, Patel AM, WanchooR, et al. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007; 83: 290.
26. Hymes LC, Greenbaum L, Amaral SG, et al. Surveillance renal transplant biopsies and subclinical rejectionatthree months post-transplant in pediatric recipients. Pediatr Transplant 2007; 11: 536.
27. Hymes LC, Warshaw BL, Amaral SG, et al. Tacrolimus withdrawal and conversionto sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 2008; 12: 773.
28. Caliendo AM, St George K, Kao SY, et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: Clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000; 38: 2122.
29. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094.
30. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: Late-onset disease and indirect consequences. Clin Infect Dis 2008; 46: 732.
31. Kotton CN, Kumar D, Caliendo AM, et al. International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. The Transplantation Society International CMV Consensus Group Transplantation 2010; 89: 779.